Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates And Development Pipeline In Letter To Shareholders

Author: Benzinga Newsdesk | March 05, 2024 09:47am

THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications and next-generation molecules continues.
Shareholder Letter available in Investor Relations section of MAIA's corporate website.

Letter Highlights

THIO-101 Phase 2 clinical trial nears completion; survival and response data updates forthcoming.
Along with NSCLC, MAIA's pipeline of immuno-oncology therapies includes multiple hard-to-treat cancers.
More than 80 THIO-like compounds have been developed for the Company's second-generation telomere targeting program.
Company's pipeline includes THIO-102 Phase 2 and THIO-103 Phase 2/3 clinical trials (planning stage), and Investigational New Drug (IND)-enabling studies for second-generation telomere targeting agents.

Posted In: MAIA